Búsqueda

IDIOMA/LANGUAGE

Bandera inglesa Bandera espanola

Publicaciones

  • CONGRESO
AASLD

Turnes J, Domínguez-Hernández R, Casado MA

Health outcomes and costs associated with the implementation of a national treatment plan for hepatitis C in Spain

68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, EEUU. 20-24 oct 2017

 

American Association for the Study of Liver Diseases

Buti M. Dominguez-Hernandez R, Casado MA

Ledispavir/Sofosbuvir (LDV/SOF) treatment of naïve patients with mild Chronic Hepatitis C (CHC) Genotype 1 (GT1)  compared to patients with significant fibrosis: is it a cost-effective therapy?

The Liver Meeting®, AASLD’s 67th Annual Meeting in Boston, EEUU. 11-15 nov 2016

Comunicaciones AASLD

Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, Casado MA

Cost-effectiveness analysis of telaprevir triple therapy for treatment-naïve patients with chronic hepatitis C based on the combined efficacy of the ADVANCE and OPTIMIZE studies.

The Liver Meeting®, AASLD’s 64th Annual Meeting in Washington, EEUU. 1-5 nov 2013.

Comunicaciones AASLD

Turnes J, Oyagüez I, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Solà R, Casado MA, Romero-Gómez M

Cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients.

The Liver Meeting®, AASLD’s 64th Annual Meeting in Washington, DC, 1-5 Noviembre 2013.

Comunicaciones AASLD

Buti M, Brosa M, Casado MA, Rueda M, Esteban R

Estimating the impact of chronic hepatitis B on future liver-related morbility, mortality and cost in Spain.

58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts. 2-6 nov 2007.

Comunicaciones AASLD

Buti M, Casado MA, Esteban R

Therapy a la carte is more cost-effective than standard combination therapy for naïve patients with chronic hepatitis C.

57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts. 27-31 oct 2006.

Comunicaciones EASL

Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R

The improved therapeutic effects of adefovir dipivoxil in patients with HBe-Ag-negative chronic hepatitis B offset against its increased cost compared to lamivudine.

41st Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria. 26-30 apr 2006.

Comunicaciones AASLD

Wong JB, Buti M, Casado MA, Fosbrook L, Soriano V, Esteban R

Cost-effectiveness of peginterferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-HCV co-infected patients.

56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and awarded a Presidential Poster of Distinction. San Francisco, California, EEUU. 11-15 nov 2005.

Comunicaciones AASLD

Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R

Long-term treatment with adefovir dipivoxil is more cost-effective than lamivudine for HBeAg-negative patients with chronic hepatitis B.

56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, California, EEUU. 11-15 nov 2005.

Comunicaciones AASLD

Buti M, Casado MA, Fosbrook L, Esteban R

Budget impact analysis of two different methods of evaluating EVR to peginterferon alfa-2b (PegIntron?) plus ribavirin (Rebetol) in genotype 1 naïve patients with chronic hepatitis C.

55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts. 29 oct-2 nov 2004.